The nTRACK was a 4-year EU Horizon 2020 project that started in October 2017  and finished in September 2021. This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 761031 (€ 6,907 million grant).

This project had the aim to develop a safe and highly sensitive multimodal nano imaging agent enabling non-invasive, quantitative and longitudinal stem cell tracking and whole-body bio distribution. nTRACK also provides information on cell (long-term) viability using the combination of CT, MRI and PET, which are imaging modalities that are clinically available. The synthesis of nTRACK NPs and cellular labelling processes will be scaled up and will follow good manufacturing practice (GMP) requirements. A second goal was to establish a predictive model for early assessment of treatment effectiveness, based on short-term evaluation of the typical migration and bio distribution patterns of the stem cells. This predictive model could substantially improve overall management of the disease and will transform cell therapy treatment from “one size fits all’ concept towards personalised treatment.

The n-TRACK Project Partners were LEITAT, Asphalion, BIOEMTECH, Cambridge Nanomaterials Technology Ltd, MJR PharmJet GmbH, RIVM, Unimedizin Mainz (UMC), Vivotecnia Research S.L, Vall d’Hebron Research Institute (VHIR), Bar Ilan University, Pluristem Therapeutics and National Center for Scientific Research “Demokritos”.